GlassScriptPhysician profile
Daman Bowman
NPI 1922568328
$1,246.12
in general payments reported to CMS, 2019-2025
9 companies · $412 in 2025
The $412 reported for 2025 was more than what a typical Colon & Rectal Surgery provider received nationally (typical 2025 total: $317).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $72.69 · 2022: $261 · 2023: $255 · 2024: $246 · 2025: $412.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $913.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $912.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $315.01 | 2021-2024 | Dextile |
| Smith+Nephew, INC. | $164.19 | 2025 | Renasys Go V2 Home |
| Boston Scientific Corporation | $150.00 | 2024 | |
| W. L. Gore & Associates, INC. | $149.93 | 2025 | Gore Propaten Vascular Graft |
| Coloplast Corp | $144.14 | 2023 | Sensura Mio |
| Takeda Pharmaceuticals U.S.A., INC. | $110.88 | 2023 | Gattex |
| Ethicon US, LLC | $97.86 | 2025 | Echelon; Endopath |
| Haemonetics Corporation | $94.65 | 2022 | |
| Edwards Lifesciences Corporation | $19.46 | 2024 | Mitris Resilia Mitral Valve |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daman Bowman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.